BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 20018266)

  • 21. Tularemia in BALB/c and C57BL/6 mice vaccinated with Francisella tularensis LVS and challenged intradermally, or by aerosol with virulent isolates of the pathogen: protection varies depending on pathogen virulence, route of exposure, and host genetic background.
    Chen W; Shen H; Webb A; KuoLee R; Conlan JW
    Vaccine; 2003 Sep; 21(25-26):3690-700. PubMed ID: 12922099
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of Schu S4
    Cunningham AL; Mann BJ; Qin A; Santiago AE; Grassel C; Lipsky M; Vogel SN; Barry EM
    Virulence; 2020 Dec; 11(1):283-294. PubMed ID: 32241221
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of Francisella tularensis Schu S4 defined mutants as live-attenuated vaccine candidates.
    Santiago AE; Mann BJ; Qin A; Cunningham AL; Cole LE; Grassel C; Vogel SN; Levine MM; Barry EM
    Pathog Dis; 2015 Aug; 73(6):ftv036. PubMed ID: 25986219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral immunization of mice with the live vaccine strain (LVS) of Francisella tularensis protects mice against respiratory challenge with virulent type A F. tularensis.
    KuoLee R; Harris G; Conlan JW; Chen W
    Vaccine; 2007 May; 25(19):3781-91. PubMed ID: 17346863
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protection afforded against aerosol challenge by systemic immunisation with inactivated Francisella tularensis live vaccine strain (LVS).
    Eyles JE; Hartley MG; Laws TR; Oyston PC; Griffin KF; Titball RW
    Microb Pathog; 2008 Feb; 44(2):164-8. PubMed ID: 17904793
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Francisella tularensis SCHU S4 mutant deficient in γ-glutamyltransferase activity induces protective immunity: characterization of an attenuated vaccine candidate.
    Ireland PM; LeButt H; Thomas RM; Oyston PCF
    Microbiology (Reading); 2011 Nov; 157(Pt 11):3172-3179. PubMed ID: 21852349
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of Francisella tularensis ΔpdpC as a candidate live attenuated vaccine against respiratory challenge by a virulent SCHU P9 strain of Francisella tularensis in a C57BL/6J mouse model.
    Tian D; Uda A; Park ES; Hotta A; Fujita O; Yamada A; Hirayama K; Hotta K; Koyama Y; Azaki M; Morikawa S
    Microbiol Immunol; 2018 Jan; 62(1):24-33. PubMed ID: 29171073
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral live vaccine strain-induced protective immunity against pulmonary Francisella tularensis challenge is mediated by CD4+ T cells and antibodies, including immunoglobulin A.
    Ray HJ; Cong Y; Murthy AK; Selby DM; Klose KE; Barker JR; Guentzel MN; Arulanandam BP
    Clin Vaccine Immunol; 2009 Apr; 16(4):444-52. PubMed ID: 19211773
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cellular and humoral immunity are synergistic in protection against types A and B Francisella tularensis.
    Sebastian S; Pinkham JT; Lynch JG; Ross RA; Reinap B; Blalock LT; Conlan JW; Kasper DL
    Vaccine; 2009 Jan; 27(4):597-605. PubMed ID: 19022323
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Deletion of IglH in virulent Francisella tularensis subsp. holarctica FSC200 strain results in attenuation and provides protection against the challenge with the parental strain.
    Straskova A; Cerveny L; Spidlova P; Dankova V; Belcic D; Santic M; Stulik J
    Microbes Infect; 2012 Feb; 14(2):177-87. PubMed ID: 21930232
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Susceptibility of various mouse strains to systemically- or aerosol-initiated tularemia by virulent type A Francisella tularensis before and after immunization with the attenuated live vaccine strain of the pathogen.
    Shen H; Chen W; Conlan JW
    Vaccine; 2004 Jun; 22(17-18):2116-21. PubMed ID: 15149767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Contributions of TolC Orthologs to
    Kopping EJ; Doyle CR; Sampath V; Thanassi DG
    Infect Immun; 2019 Apr; 87(4):. PubMed ID: 30670554
    [No Abstract]   [Full Text] [Related]  

  • 33. Vaccination of Fischer 344 rats against pulmonary infections by Francisella tularensis type A strains.
    Wu TH; Zsemlye JL; Statom GL; Hutt JA; Schrader RM; Scrymgeour AA; Lyons CR
    Vaccine; 2009 Jul; 27(34):4684-93. PubMed ID: 19520198
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic modification of the O-polysaccharide of Francisella tularensis results in an avirulent live attenuated vaccine.
    Kim TH; Pinkham JT; Heninger SJ; Chalabaev S; Kasper DL
    J Infect Dis; 2012 Apr; 205(7):1056-65. PubMed ID: 21969334
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Francisella tularensis type B ΔdsbA mutant protects against type A strain and induces strong inflammatory cytokine and Th1-like antibody response in vivo.
    Straskova A; Spidlova P; Mou S; Worsham P; Putzova D; Pavkova I; Stulik J
    Pathog Dis; 2015 Nov; 73(8):ftv058. PubMed ID: 26253078
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Respiratory and oral vaccination improves protection conferred by the live vaccine strain against pneumonic tularemia in the rabbit model.
    Stinson E; Smith LP; Cole KS; Barry EM; Reed DS
    Pathog Dis; 2016 Oct; 74(7):. PubMed ID: 27511964
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Francisella tularensis locus required for spermine responsiveness is necessary for virulence.
    Russo BC; Horzempa J; O'Dee DM; Schmitt DM; Brown MJ; Carlson PE; Xavier RJ; Nau GJ
    Infect Immun; 2011 Sep; 79(9):3665-76. PubMed ID: 21670171
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Attenuation and protective efficacy of an O-antigen-deficient mutant of Francisella tularensis LVS.
    Li J; Ryder C; Mandal M; Ahmed F; Azadi P; Snyder DS; Pechous RD; Zahrt T; Inzana TJ
    Microbiology (Reading); 2007 Sep; 153(Pt 9):3141-3153. PubMed ID: 17768257
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Models derived from in vitro analyses of spleen, liver, and lung leukocyte functions predict vaccine efficacy against the Francisella tularensis Live Vaccine Strain (LVS).
    De Pascalis R; Chou AY; Ryden P; Kennett NJ; Sjöstedt A; Elkins KL
    mBio; 2014 Apr; 5(2):e00936. PubMed ID: 24713322
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Kdo hydrolase is required for Francisella tularensis virulence and evasion of TLR2-mediated innate immunity.
    Okan NA; Chalabaev S; Kim TH; Fink A; Ross RA; Kasper DL
    mBio; 2013 Feb; 4(1):e00638-12. PubMed ID: 23404403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.